Possibilities of aggressive oncosurgery in treatment of IIA–IIIB stages of cervical cancer

Introduction. Arming gynecological oncology with modern chemotherapy schemes, elements of aggressive oncosurgery, it is possible to achieve an increase in the number of cured patients with locally advanced forms of cervical cancer (CC), providing an improvement in the immediate and long-term results of treatment. The proposed method of surgical treatment is the method of choice for the surgical treatment of patients with locally advanced forms of cervical cancer (stages IIA–IIIB).

Purpose of the study. Introduction into clinical practice of the method of surgical treatment of IIA–IIIB stages of cervical cancer.

Material and methods. Long-term results of treatment of 155 patients with morphologically verified stage IIA–IIIB cervical cancer were studied. The patients underwent neoadjuvant chemotherapy (NACT) (n = 110) and chemoradiotherapy (CRT) (n = 45). When resectability was achieved, the patients underwent surgical treatment using a new technique. Overall survival (OS) and progression-free survival (PFS) outcomes were assessed.

Results. In the period from 2017 to 2020, 155 patients with stage IIA–IIIB cervical cancer after NACT (n = 110) and CRT (n = 45) underwent combinedextended extirpation of the uterus with appendages according to our patented method. The most frequent postoperative complications were urination disorders in 106 (67 [60.9%] and 19 [42.2%]) patients, lymphatic cysts in 30 (20 [18.2%] and 10 [22.2%]) patients and vesicovaginal fistula in 7 patients (5 [4.6%] and 2 [4.4%]), respectively. According to the results of a pathomorphological study, the most frequent tumor response to NACT was III degree of therapeutic pathomorphosis (TP) in 44 (40.0%) patients of group 1 and in 21 patients – IV-degree TP, amounting to 46.6%. The median follow-up was 28.7 (from 3.6 to 51.1) months. During this time, 30 patients died in both groups (17 [15.5%] and 13 [28.9%]) (p = 0.047). Disease progression occurred in 16 (10.3%) patients (6 [5.5%] and 10 [22.2%]) (p = 0.004), respectively. The 3-year OS was 83.8 ± 3.7 and 71.0 ± 6.8 (p = 0.131), PFS – 93.5 ± 2.6 and 77.7 ± 6.6 (p = 0.006).

Conclusions. The proposed method of surgical treatment of IIA–IIIB stages of cervical cancer has a novelty and can be used in practical medicine for the surgical treatment of oncology diseases in cervical cancer

1. Moshkovich O., Lebrun-Harris L., Makaroff L. et al. Challenges and opportunities to improve cervical cancer screening rates in US health centers through patient-centered medical home transformation. Adv Prev Med. 2015; 2015: 182073. DOI: 10.1155/2015/182073.

2. Ferlay J., Colombet M., Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15; 144 (8): 1941–1953. DOI: 10.1002/ijc.31937.

3. Каприн А. Д., Старинский В.В., Петрова Г. В. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М., 2018. 250 с.

4. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). M., 2018. 250 p.

5. Рейес Сантьяго Д.К., Хаджимба А.С., Соболев И.В. и др. Результаты комбинированного лечения рака шейки матки IIA–IIIB стадий. Опухоли женской репродуктивной системы 2018; 14 (4): 50–5.

6. Reyes Santiago D.K., Khadzhimba A.S., Sobolev I.V. et al. Results of combined treatment of stage IIA–IIIB cervical cancer. Tumors of the female reproductive system 2018; 14 (4): 50–5.

7. Gong Lin M.D., Zhang Jia-Wen M.D., Yin Ru-Tie M.D. et al. Safety and efficacy of neoadjuvant chemotherapy followed by radical surgery versus radical surgery alone in locally advanced cervical cancer patient. Int J Gynecol Cancer 2016; 26 (4): 722–8. PMID: 26905330. DOI: 10.1097/IGC.0000000000000658.

8. Park J.Y., Kim D.Y., Kim J.H. et al. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. J Gynecol Oncol 2012; 23 (4): 226–34. PMID: 23094125. DOI: 10.3802/jgo.2012.23.4.226.

9. Katsumata N., Yoshikawa H., Kobayashi H. et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: A Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 2013; 108 (4): 1957–63. PMID: 23640393. DOI: 10.1038/bjc.2013.179.

10. Landoni F., Sartori E., Maggino T. et al. Is there a role for postoperative treatment in patients with stage Ib2–IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol Oncol 2014; 132 (3): 611–7. DOI: 10.1016/j.ygyno.2013.12.010.

11. Оводенко Д.Л., Хабас Г.Н., Крейнина Ю.М. и др. Рак шейки матки стадий IB2–IIIB: неоадъювантная химиотерапия, радикальные операции и выживаемость пациенток. Сибирский онкологический журнал. 2021; 20 (3): 82–89. DOI: 10.21294/1814–4861–2021–20–3–82–89.

12. Ovodenko D.L., Khabas G.N., Kreinina Yu.M. Cervical cancer stages IB2-IIIB: neoadjuvant chemotherapy, radical surgery and patient survival. Siberian journal of oncology. 2021; 20 (3): 82–89. DOI: 10.21294/1814–4861–2021–20–3–82–89.

13. Sao Paulo Medical Journal. RPM 112 (2) Apr/May/Jun 1994. 11. Frutuoso C, Amaral N, Marques C et al. [Wertheim-Meigs procedure. 10-year results]. Acta Med Port. 1997 Oct; 10 (10): 631–6. Portuguese. PMID: 9477585.